- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT03028883
Buprenorphine Dose Adjustments and Gestational Age
Relationship Between Buprenorphine Dose Adjustments and Gestational Age in the Treatment of Opioid-Maintained Pregnant Women
연구 개요
상세 설명
The prevalence of opioid use disorder in pregnancy was four per 1000 deliveries in 2011 and has increased to 5.4% in 2013. Repeated, acute withdrawal during pregnancy is not recommended as it is may be associated with intrauterine growth restriction (IUGR) and preterm labor and delivery. The American College of Obstetricians and Gynecologists (ACOG) recommends methadone as the first line treatments for opioid use during pregnancy and buprenorphine as an alternative. Methadone therapy has been used since the 1970's for the treatment of heroin addiction during pregnancy and efficacy is well documented. Prescribing methadone has barriers, such as significant drug interactions and enrollment in a registered substance abuse treatment program. Emerging evidence supports the use of buprenorphine for opioid use disorder in pregnancy. Buprenorphine has some distinct advantages over methadone which include a lower risk of overdose, fewer drug interactions, and no need for registration into a methadone treatment program. However, buprenorphine has a lower rate of retention in treatment than methadone.
Opioid use disorder increases the risk of adverse pregnancy outcomes compared to women who do not use opioids.One such outcome is neonatal abstinence syndrome (NAS) which affects approximately 55% to 94% of neonates exposed to addictive medications during pregnancy. A 2016 review of five trials involving buprenorphine and methadone in pregnant patients found that buprenorphine significantly improved or had similar outcomes to methadone for neonatal outcomes. Buprenorphine exposed infants required less treatment for NAS (20%-47% vs 45.5%-57%, respectively) and experienced a shorter duration of NAS (4.1-5.6 vs 5.3-9.9 days, respectively) compared to methadone exposed infants. Buprenorphine is associated with fewer preterm deliveries and adverse fetal outcomes including the rate of NAS, medication assistance for NAS, and total dose of morphine used to treat NAS. There are currently no studies evaluating the level of buprenorphine doses on the rate of NAS.
Several pharmacokinetic changes occur during pregnancy which impact medications and increase the risk for subtherapeutic levels. Subtherapeutic buprenorphine levels may increase the risk for withdrawal symptoms and cravings, which may increase the risk for relapse. The volume of distribution increases for both hydrophilic and lipophilic medications throughout pregnancy due to increased body fluid, increased adipose tissue, and decreased protein binding. Buprenorphine is metabolized through cytochrome P450 (CYP450) 3A4, UGT1A1, 1A3, and 2B7. Pregnancy increases hepatic metabolism of the CYP450 3A4 and UGT2B7. Buprenorphine is eliminated 70% through the feces and 30% through the urine. Pregnancy increases hepatic and renal elimination. Elimination is increased partly due to increased cardiac output secondary to increased plasma volume. Cardiac output reaches its maximum at approximately 32 weeks, whereas peak renal elimination occurs at 36 weeks. These pharmacokinetic changes typically require doses to be increased as pregnancy progresses.
A limitation of methadone therapy is the unpredictable pharmacokinetics during pregnancy. Methadone is a lipophilic and highly protein-bound medication, making the medication less available during pregnancy. It is metabolized mainly by CYP3A4, which leads to decreased concentrations of methadone in the plasma during pregnancy. One study performed by Pond and colleagues examined methadone serum concentrations during the second and third trimesters and at two separate time points post-partum. They found plasma trough methadone concentrations were lower and methadone renal clearance was higher in the second and third trimesters than in the post-partum time period, supporting the finding that methadone requires dose increases as pregnancy progresses. A literature review explored studies related to dosing and monitoring of methadone in pregnancy. This review included a a study that found a methadone plasma trough level of 0.78 µmol/L was required to prevent withdrawal. The authors of the review found evidence to support that methadone pharmacokinetics appear to be altered in pregnancy but that there is a lack of evidence to support routine serum monitoring. Although based on the Drozdick study they do endorse monitoring trough levels when withdrawal symptoms are apparent.
Few studies evaluated the effect of pregnancy on the pharmacokinetics of buprenorphine. Based on the characteristics of the medication it would be expected that pharmacokinetic changes in pregnancy would be similar to those of methadone. One difference is that buprenorphine has an active metabolite which may make buprenorphine dosing more predictable. the pharmacokinetics of buprenorphine in plasma, oral fluid, and sweat of pregnant women (n=9). At 28-29 and 34 weeks gestation and 2 months postpartum, plasma, oral fluid and sweat levels were collected over 24 hours. The maximum concentration and total amount of buprenorphine and norbuprenorphine in plasma were lower during pregnancy compared with postpartum levels (buprenorphine Cmax 0.2ng/mL/mg vs 1ng/mL/mg and Tmax 1.5h*ng/mL/mg vs 7h*ng/mL/mg, norbuprenorphine Cmax 3ng/mL/mg vs 13ng/mL/mg and Tmax no change). Therefore, these significant metabolic changes during pregnancy and immediately postpartum could indicate the need for dose adjustment of buprenorphine. Another small trial of nine pregnant women on buprenorphine maintenance therapy assessed the urinary excretion of buprenorphine and its metabolites every 12 days from the second trimester through 6 weeks postpartum. The mean ratio of urine buprenorphine to norbuprenorphine was significantly higher in the second trimester compared to the third trimester in all patients. Additionally, the mean dose of buprenorphine increased from the second to the third trimester in seven of the nine women. In a subset of 3 patients, 24-hour buprenorphine and metabolite excretion was collected. Buprenorphine levels were higher during pregnancy than postpartum in all three (0.8 mg, 5.0 mg, 2.0 mg vs 0.55 mg, 4.0 mg, 0.8 mg, respectively). The uncorrected buprenorphine urine concentrations ranged from 5.5 to 12.1 µg/L [mean 7.0 (2.8) µg/L], although they did not evaluate if withdrawal symptoms occurred below a certain threshold. The buprenorphine dose in this study was flexible, with increases or decreases made through clinical decisions based on compliance in taking medication, participant requests, urine toxicology, and participant self-reports of opioid withdrawal symptoms or craving. Buprenorphine dose was positively correlated to creatinine-corrected norbuprenorphine (P < 0.001, R = 0.197), buprenorphine-glucuronide (P < 0.002, R = 0.143), and norbuprenorphine-glucuronide (P < 0.001, R = 0.182) concentrations across the study. However low correlation coefficients indicate that prediction of metabolite concentrations in urine based on buprenorphine dose, or vice versa, would be unreliable. These studies support the need for increased doses of buprenorphine throughout pregnancy, but may have been too small to determine whether a relationship between buprenorphine urine levels and dose adjustments exists. Currently, no studies examined the relationship between gestational age and buprenorphine dose adjustments after having achieved maintenance dosing.
This information could assist providers in optimizing monitoring of pregnant women and informing providers regarding dose adjustments. Preventing subtherapeutic levels may decrease the risk for withdrawal symptoms, craving, and risk of relapse.
No data are available to evaluate whether a particular gestational age requires dose adjustments due to pregnancy-related pharmacokinetic changes. The program obtains quantitative and qualitative buprenorphine and norbuprenorphine urine levels at each visit. These data are used to confirm that she is taking her buprenorphine prescription. No data are available to determine if there is a lower threshold in urine buprenorphine and metabolite that levels correlate with symptoms that require dose increases. Additionally, no data are available evaluating if rates of NAS, treatment for NAS, or total dose of morphine for NAS correlates as a function of maternal dose.
연구 유형
등록 (실제)
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
샘플링 방법
연구 인구
설명
Inclusion Criteria:
- Pregnant
- opioid-dependent
- being treated at same location
Exclusion Criteria:
- Not pregnant
- not opioid-dependent
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
코호트 및 개입
그룹/코호트 |
개입 / 치료 |
---|---|
buprenorphine dose adjustments
To determine if a relationship exists between buprenorphine dose adjustments and gestational age in opioid-maintained pregnant women
|
Do higher doses of buprenorphine result in a higher rate of neonatal abstinence syndrome as compared to lower doses of buprenorphine
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
dose adjustments
기간: 9 months
|
buprenorphine dose adjustments in opioid-maintained pregnant women
|
9 months
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- 27675
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
신생아 금욕 증후군에 대한 임상 시험
-
Icahn School of Medicine at Mount SinaiNational Institute on Deafness and Other Communication Disorders (NIDCD)완전한
-
Basaksehir Cam & Sakura Şehir Hospital완전한
-
China Medical University Hospital알려지지 않은
-
Wolfson Medical Center빼는Ovarian Hyperstimulation Syndrome(OHSS)의 위험 감소를 위한 Coasting에 대한 GnRH 길항제의 증량 투여
-
Jazz Pharmaceuticals모병결절성 경화증 복합 환자의 발작 | Dravet Syndrome 참가자의 발작 | 레녹스-가스토 증후군 참가자의 발작미국
-
Cure CMD모병Emery-Dreifuss 근이영양증 | 선천성 근무력증 증후군 | 림거들 근이영양증 | ITGA7(인테그린 알파-7) 결핍을 동반한 선천성 근이영양증 | 알파-디스트로글리칸병증(심각한 간질을 동반한 디스트로글리칸의 선천성 근이영양증 및 비정상적인 글리코실화) | 알파-디스트로글리칸병증(TRAPPC11 돌연변이로 인한 지방간 및 영아 발병 백내장을 동반한 선천성 근이영양증) | 알파-디스트로글리칸병증(디스트로글리칸의 저당화를 동반한 선천성 근이영양증) | 알파-디스트로글리칸병증(디스트로글리칸 및 간질의 저당화를 동반한 선천성 근이영양증) | 알파-디스트로글리칸병증(디스트로글리칸병증... 그리고 다른 조건미국
-
Sanford HealthNational Ataxia Foundation; Beyond Batten Disease Foundation; Pitt Hopkins Research Foundation 그리고 다른 협력자들모병미토콘드리아 질병 | 색소 성 망막염 | 중증 근무력증 | 호산구성 위장염 | 다계통 위축 | 평활근육종 | 백질이영양증 | 항문 누공 | 척수소뇌성 운동실조증 3형 | 프리드라이히 실조증 | 케네디병 | 라임 병 | 혈구탐식림프조직구증 | 척수소뇌성 운동실조증 1형 | 척수소뇌성 운동실조증 2형 | 척수소뇌성 실조증 6형 | 윌리엄스 증후군 | 히르슈스프룽병 | 글리코겐 축적병 | 가와사키병 | 짧은 창자 증후군 | 저인산증 | 레버 선천성 흑암시 | 입내 | 심장이완불능증 | 다발성 내분비선 종양 | 레이 증후군 | 애디슨병 | 제2형 다발성내분비선종양 | 경피증 | 제1형 다발성내분비선종양 | 다발성 내분비선 종양 유형 2A | 다발성 내분비선 종양 유형 2B | 비정형 용혈성... 그리고 다른 조건미국, 호주
Dose adjustments에 대한 임상 시험
-
Jiangsu Province Centers for Disease Control and...Royal (Wuxi) Biological Co., LTD완전한
-
Joris B.W. ElbersErasmus Medical Center; HollandPTC모병두경부 편평 세포 암종 | 방사선 요법 | 양성자 치료 | 저분할 | 면역 체계 억제네덜란드
-
Innovent Biologics (Suzhou) Co. Ltd.정지된
-
Third Affiliated Hospital, Sun Yat-Sen University알려지지 않은
-
University of MiamiNational Cancer Institute (NCI)완전한
-
Memorial Sloan Kettering Cancer Center완전한
-
Seoul National University HospitalGreen Cross Corporation; LSK Global Pharma Services Co. Ltd.완전한